{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":247,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":247,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"4aa5585a87ca","filters":{"venue":"SKIN The Journal of Cutaneous Medicine"}},"results":[{"id":"W3103502969","doi":"10.25251/skin.4.supp.95","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Double blind; Medicine; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","authors":[{"name":"Kim Papp","is_ca":true},{"name":"Jacek C. Szepietowski","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Michael E. Kuligowski","is_ca":false},{"name":"May E. Venturanza","is_ca":false},{"name":"Kang Sun","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05448425355856354,"gpt":0.3643731436587562,"spread":0.3098888901001927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005903119,0.0001969571,0.001511796,0.00006460131,0.0001053762,0.000003149645,0.0001645125,0.00004775644,0.00004505764],"category_scores_gemma":[0.002079273,0.00008197424,0.0002349994,0.0001082327,0.001059165,0.00003170231,0.00002112366,0.0001432681,7.700997e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000238991,"about_ca_system_score_gemma":0.0001049512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005064168,"about_ca_topic_score_gemma":0.000008491478,"domain_scores_codex":[0.9977875,0.0002427518,0.001344936,0.0001209317,0.000343112,0.0001607544],"domain_scores_gemma":[0.9878539,0.01038188,0.000987266,0.0002522969,0.00035889,0.0001657834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9542939,0.0007501078,0.0001340733,0.000212957,0.004678908,0.0005307205,0.02207506,0.00009237423,0.0001836497,0.0001322499,0.006620195,0.01029583],"study_design_scores_gemma":[0.9613365,0.004840501,0.0002315676,0.001026779,0.008989877,0.004385563,0.005316957,0.0003865737,0.004004281,0.0009443895,0.00844028,0.00009672636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8710784,0.08505747,0.0003114163,0.04106794,0.0003032389,0.001721757,0.0001039771,0.000008889353,0.0003468916],"genre_scores_gemma":[0.9695106,0.02873486,0.0001452637,0.0008005761,0.0007057007,0.000008514567,0.00001784781,0.00001307824,0.00006360177],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09843213,"threshold_uncertainty_score":0.3902538,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102502247","doi":"10.25251/skin.4.supp.75","title":"Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada); Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology; Phase (matter); Clinical trial; Internal medicine; Physics","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Hwanhee Hong","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Jeff Fromowitz","is_ca":false},{"name":"Scott Guenthner","is_ca":false},{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"David S. Rubenstein","is_ca":false},{"name":"Philip Brown","is_ca":false},{"name":"Anna M. Tallman","is_ca":false},{"name":"Robert Bissonnette","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06043474788367265,"gpt":0.3426864154785979,"spread":0.2822516675949253,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009525694,0.0001265797,0.0005355746,0.000008321475,0.00009635734,0.000005067403,0.0002619354,0.00003358908,0.00009473869],"category_scores_gemma":[0.0009189695,0.00003061368,0.00008830229,0.0001850703,0.0001848446,0.00002185791,0.00001227382,0.0001198285,6.127043e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002707595,"about_ca_system_score_gemma":0.00002062264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006750275,"about_ca_topic_score_gemma":0.00005677655,"domain_scores_codex":[0.9986539,0.0001425943,0.0007201921,0.0001008831,0.0002443609,0.000138041],"domain_scores_gemma":[0.9927329,0.006442808,0.0005682874,0.00005718238,0.00008189099,0.0001169245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01361901,0.001001263,0.00008360598,0.00003291071,0.00025012,0.00007154657,0.00387387,0.0001368204,0.7608389,0.00007894193,0.004871153,0.2151419],"study_design_scores_gemma":[0.08515202,0.1218423,0.006420623,0.002026286,0.005504033,0.01719698,0.02963722,0.00322971,0.2459576,0.005846984,0.4761496,0.001036615],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9523174,0.00374493,0.00006694734,0.04282606,0.00009435548,0.0007440665,0.00006920753,0.00000517373,0.0001318916],"genre_scores_gemma":[0.9938451,0.004299064,0.00003180363,0.0002248735,0.00154555,0.000009914255,0.00001100994,0.000001169851,0.00003151293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5148813,"threshold_uncertainty_score":0.1248389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4229015785","doi":"10.25251/skin.6.supp.s29","title":"Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics; Physics","authors":[{"name":"Amy S. Paller","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Weily Soong","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Marie L. A. Schuttelaar","is_ca":false},{"name":"Petra Amoudruz","is_ca":false},{"name":"Azra Kurbasic","is_ca":false},{"name":"Lise Soldbro","is_ca":false},{"name":"Katja Wendicke Lophaven","is_ca":false},{"name":"Michael J. Cork","is_ca":false},{"name":"Anthony Bewley","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01069320491428947,"gpt":0.2697512616344214,"spread":0.2590580567201319,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006111004,0.0001444517,0.0006512871,0.0001576045,0.0001095346,0.000002145498,0.000270001,0.00003917556,0.00005137452],"category_scores_gemma":[0.0004525249,0.00007084042,0.00007259937,0.0003199915,0.0003080069,0.00003327727,0.00006014063,0.0004985723,2.757959e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005214063,"about_ca_system_score_gemma":0.0002459536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003120385,"about_ca_topic_score_gemma":0.00002649259,"domain_scores_codex":[0.9976749,0.0004419698,0.0009449515,0.0001071437,0.000654111,0.0001768677],"domain_scores_gemma":[0.9985798,0.0002750415,0.0006014812,0.0002923743,0.0001261805,0.0001251137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9425498,0.003245428,0.009631358,0.0006375422,0.0005245502,0.004232298,0.01488614,0.004769918,0.0008107653,0.00004147376,0.01159286,0.007077873],"study_design_scores_gemma":[0.7205837,0.01753288,0.09055467,0.009684711,0.002234746,0.1456626,0.006409325,0.0006694116,0.002808233,0.0007037433,0.002791091,0.0003648841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915348,0.001245813,0.00002334367,0.005875182,0.0002444828,0.0007257473,0.00002668893,0.000003757229,0.0003201817],"genre_scores_gemma":[0.9988162,0.000143391,0.00002116237,0.0008239287,0.0001064308,0.000003113913,0.000002660159,0.00001264207,0.00007045521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2219661,"threshold_uncertainty_score":0.2888789,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3135451264","doi":"10.25251/skin.5.supp.32","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Medicine; Psoriasis; Dermatology; Psychology; Pathology; Neuroscience","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"C. Paul","is_ca":false},{"name":"L. Puig","is_ca":false},{"name":"Kristian Reich","is_ca":false},{"name":"Peter van der Kerkhof","is_ca":false},{"name":"Sven Richter","is_ca":false},{"name":"Benolt Guerette","is_ca":false},{"name":"Paolo Gisondi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05909140626378356,"gpt":0.2805296217580594,"spread":0.2214382154942758,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004740743,0.0001431119,0.0003508263,0.0000677537,0.0004198235,0.00001288441,0.0001485877,0.00002081941,0.0002460711],"category_scores_gemma":[0.0004838024,0.00007023681,0.0001386105,0.00007360999,0.0002154431,0.00005454289,0.0000159265,0.00009756244,0.000001264248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000318724,"about_ca_system_score_gemma":0.0004004141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001091669,"about_ca_topic_score_gemma":0.00242562,"domain_scores_codex":[0.9979482,0.0004217968,0.0008929738,0.0001110409,0.0004591303,0.0001668394],"domain_scores_gemma":[0.9962838,0.002023333,0.0009564759,0.0002822256,0.0002655656,0.0001886497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"qualitative","study_design_gemma":"qualitative","study_design_scores_codex":[0.03722383,0.003261702,0.017224,0.001604515,0.002137988,0.0002626077,0.8169367,0.004360942,0.0002700147,0.06838436,0.03745087,0.01088249],"study_design_scores_gemma":[0.02285154,0.01019655,0.1014936,0.01077196,0.007840861,0.0002952247,0.5409834,0.006657774,0.0001182183,0.2714003,0.0264744,0.0009161388],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775047,0.01239751,0.0007378592,0.00484034,0.003034887,0.0004826056,0.0006515852,0.000005749902,0.0003447938],"genre_scores_gemma":[0.9973186,0.0009716901,0.00002846466,0.0001861607,0.001184727,0.000003634281,0.00009162194,0.00001334054,0.0002017851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2759533,"threshold_uncertainty_score":0.3228985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388626033","doi":"10.25251/skin.7.supp.286","title":"Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Internal medicine; Dosing; Intertriginous; Adverse effect; Gastroenterology; Adalimumab; Surgery; Pathology; Tumor necrosis factor alpha","authors":[{"name":"Afsáneh Alavi","is_ca":false},{"name":"Errol P. Prens","is_ca":false},{"name":"Alexa B. Kimball","is_ca":true},{"name":"James G. Krueger","is_ca":false},{"name":"Sutirtha Mukhopadhyay","is_ca":false},{"name":"Hui Wang","is_ca":false},{"name":"Nathalie Ivanhoff","is_ca":false},{"name":"A.C. Hernández","is_ca":false},{"name":"Christos C. Zouboulis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03057522950790823,"gpt":0.3238723228457288,"spread":0.2932970933378206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001024365,0.0002640351,0.0009557949,0.0003457477,0.0001457559,0.00000798836,0.0002881517,0.00007776875,0.0002996543],"category_scores_gemma":[0.0008327432,0.000137281,0.0002089379,0.0006269543,0.0003262329,0.00009486969,0.00003987289,0.0003360164,0.00001277428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008618808,"about_ca_system_score_gemma":0.000220659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003073855,"about_ca_topic_score_gemma":0.00001754532,"domain_scores_codex":[0.9973477,0.0002002504,0.001031079,0.0001633946,0.0008879285,0.0003697046],"domain_scores_gemma":[0.997206,0.001103735,0.0006257676,0.0003566863,0.0005043306,0.0002034571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.01630152,0.007200258,0.01563142,0.0009425809,0.007824472,0.4638843,0.1961899,0.00007726997,0.01670035,0.000390431,0.1106866,0.1641709],"study_design_scores_gemma":[0.01890219,0.04275546,0.001434183,0.001312502,0.003579208,0.8682458,0.03401554,0.0002736573,0.02201683,0.001989752,0.00516825,0.0003065751],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9063765,0.002038394,0.0008671886,0.08212325,0.001612083,0.004483123,0.000069685,0.00007590964,0.002353845],"genre_scores_gemma":[0.9960129,0.00009056086,0.0001837031,0.00002892321,0.0009767329,0.00001787066,0.00001914279,0.00004722571,0.002622957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4043616,"threshold_uncertainty_score":0.5598157,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120199534","doi":"10.25251/skin.5.supp.18","title":"Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Post-hoc analysis; Scalp; Medicine; Dermatology; Nail (fastener); Psoriasis; Post hoc; Dentistry; Internal medicine; Structural engineering; Engineering","authors":[{"name":"KA Papp","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"A.B. Gottlieb","is_ca":false},{"name":"Michael Sebastian","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Yukari Okubo","is_ca":false},{"name":"M Wang","is_ca":false},{"name":"Christopher L. Cioffi","is_ca":false},{"name":"Fabienne Staelens","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02446779732439922,"gpt":0.2752013117497734,"spread":0.2507335144253741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004693984,0.000313614,0.0008935965,0.00008844387,0.0004134841,0.00001773704,0.000311134,0.0001268429,0.0003607865],"category_scores_gemma":[0.00009560064,0.0001184434,0.0002800132,0.0003543004,0.0002742801,0.00004909351,0.00003458877,0.000154061,0.000002768678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008794812,"about_ca_system_score_gemma":0.000189526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007099506,"about_ca_topic_score_gemma":0.00154869,"domain_scores_codex":[0.9981043,0.0005204699,0.0006704484,0.0002353146,0.0001850373,0.0002844168],"domain_scores_gemma":[0.9955289,0.003065221,0.0005399192,0.0004816598,0.0003319581,0.00005234331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6853713,0.003004952,0.000343583,0.00003810301,0.06447086,0.0007643308,0.06418259,0.001216296,0.02957361,0.0001285972,0.009241121,0.1416647],"study_design_scores_gemma":[0.3821472,0.1250268,0.0007865437,0.0007125029,0.1089665,0.01219146,0.05957538,0.0002004439,0.1841514,0.001356201,0.123874,0.001011652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636093,0.02378514,0.000665667,0.009790182,0.0007420176,0.0008144661,0.0005479179,0.000007211759,0.00003804401],"genre_scores_gemma":[0.9851497,0.01232811,0.0002835155,0.000940398,0.0005332411,0.00003721789,0.0001852523,0.00002334483,0.0005192347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3032241,"threshold_uncertainty_score":0.4829981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3211628515","doi":"10.25251/skin.5.supp.42","title":"Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Roflumilast; Dermis; Psoriasis; Medicine; Pharmacology; Phosphodiesterase inhibitor; Dermatology; Internal medicine; Pathology","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Angela Moore","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Lawrence Green","is_ca":false},{"name":"Adelaide A Herbert","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Jerry Bagel","is_ca":false},{"name":"Neal Bhatia","is_ca":false},{"name":"Laura K. Ferris","is_ca":false},{"name":"Terry M. Jones","is_ca":false},{"name":"Steve Kempers","is_ca":false},{"name":"David M. Pariser","is_ca":false},{"name":"Paul S. Yamauchi","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Amy Feng","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01646162550159773,"gpt":0.301729772481566,"spread":0.2852681469799683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001015471,0.0001867071,0.0005315599,0.00005959343,0.00009015379,0.00001519299,0.00008384697,0.00009342413,0.00001450886],"category_scores_gemma":[0.0007868715,0.00008954258,0.0001011691,0.0001162789,0.0002058161,0.000007567716,0.00002673731,0.0001060582,2.1831e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000384579,"about_ca_system_score_gemma":0.0001141268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003805788,"about_ca_topic_score_gemma":0.00008178385,"domain_scores_codex":[0.9980171,0.0007467144,0.0006736135,0.0001614998,0.0002565132,0.0001445111],"domain_scores_gemma":[0.9984088,0.0005918856,0.0005058309,0.0002070108,0.0002074699,0.00007903334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01041201,0.00151267,0.001377068,0.0001297824,0.00078221,0.0007834822,0.01125846,0.0001369168,0.7550809,0.00002226122,0.003915476,0.2145887],"study_design_scores_gemma":[0.02179771,0.01590803,0.003441083,0.0005715493,0.001048461,0.02036591,0.00735194,0.00009918057,0.8971017,0.000322338,0.03172624,0.0002658324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797246,0.01653105,0.000219181,0.00257047,0.0003389136,0.0004594406,0.000009357431,0.000001768131,0.0001452303],"genre_scores_gemma":[0.9911585,0.007651573,0.00007750999,0.0003753931,0.0005005593,0.000009928881,0.00001381926,0.00001145736,0.0002012227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2143229,"threshold_uncertainty_score":0.365144,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3107702560","doi":"10.25251/skin.4.supp.28","title":"BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase 2; Pharmacology; Dermatology; Platelet-derived growth factor receptor; Receptor","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Melinda Gooderham","is_ca":true},{"name":"Akimichi Morita","is_ca":false},{"name":"Peter Foley","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Sundeep Kundu","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Lan Wei","is_ca":false},{"name":"Subhashis Banergee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04346348799405544,"gpt":0.3554140720406386,"spread":0.3119505840465832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002820306,0.0001730029,0.0006654095,0.000588678,0.00002005755,0.000002311106,0.0001266239,0.0001172868,0.00003043055],"category_scores_gemma":[0.003255407,0.0001102721,0.00003670346,0.001265332,0.0001106446,0.00005170703,0.00001569039,0.0003609999,0.000001927728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005774842,"about_ca_system_score_gemma":0.0003982754,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002177286,"about_ca_topic_score_gemma":0.001712465,"domain_scores_codex":[0.9968356,0.00143547,0.0008569111,0.0001901206,0.0004766273,0.0002052224],"domain_scores_gemma":[0.9982823,0.0006801584,0.0003653124,0.0001833248,0.0003273995,0.0001615731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7143347,0.007027923,0.01948439,0.0000495235,0.0001118928,0.0006167919,0.04182194,0.001881491,0.1861465,0.000006698452,0.0006249431,0.02789322],"study_design_scores_gemma":[0.5701171,0.203232,0.0690505,0.002497178,0.001198604,0.0003713927,0.01235927,0.002751799,0.1358245,0.0004115368,0.001606687,0.0005794411],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985497,0.0003993142,0.000002726954,0.01226638,0.0001393454,0.001653209,0.00002216195,0.000004031938,0.0000158259],"genre_scores_gemma":[0.9986443,0.0001685169,0.0001126387,0.0007946718,0.0001887178,0.00005778102,0.0000158509,0.00001349708,0.000004032247],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.196204,"threshold_uncertainty_score":0.4496767,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102280768","doi":"10.25251/skin.4.supp.96","title":"Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research; University of Toronto","funders":"","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Physics","authors":[{"name":"Eric L. Simpson","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Margitta Worm","is_ca":false},{"name":"Charles Lynde","is_ca":true},{"name":"Hidehisa Saeki","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Andreas Wollenberg","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01976814871375346,"gpt":0.28888757321425,"spread":0.2691194245004965,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005076998,0.0002500977,0.001325269,0.0001426136,0.00006399426,0.000009211586,0.0001617968,0.00008251987,0.00007986045],"category_scores_gemma":[0.001756254,0.000136284,0.00006694598,0.0002071152,0.000276736,0.00008887367,0.00002084175,0.0003856244,0.000001364013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002624604,"about_ca_system_score_gemma":0.0001227801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007487187,"about_ca_topic_score_gemma":0.00003347752,"domain_scores_codex":[0.9971847,0.0004576774,0.001454023,0.0002069916,0.000479311,0.0002173001],"domain_scores_gemma":[0.996735,0.001702365,0.0007094629,0.0002161006,0.0002542424,0.0003828106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.693165,0.003568283,0.07187861,0.0006911059,0.003361722,0.008808049,0.0782856,0.001981227,0.001976402,0.00008597102,0.02039687,0.1158011],"study_design_scores_gemma":[0.6361489,0.02325893,0.2947492,0.009602846,0.00433479,0.01478315,0.004423442,0.00289022,0.004213054,0.001605722,0.003040743,0.0009489573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819376,0.002070297,0.0001875259,0.01472201,0.00009116607,0.000711991,0.0001186498,0.00001024571,0.0001504522],"genre_scores_gemma":[0.9943379,0.001455245,0.0003105991,0.003582067,0.0002482284,0.000001922107,0.00002802857,0.00002324913,0.00001281336],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2228706,"threshold_uncertainty_score":0.55575,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3121057262","doi":"10.25251/skin.5.supp.3","title":"Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Interim; Vismodegib; Internal medicine; Oncology; Medicine; Interim analysis; Basal cell; Clinical trial; History","authors":[{"name":"Karl D. Lewis","is_ca":false},{"name":"K. Peris","is_ca":false},{"name":"Aleksandar Sekulić","is_ca":false},{"name":"Alexander Stratigos","is_ca":false},{"name":"Lara Dunn","is_ca":false},{"name":"Zeynep Eroglu","is_ca":false},{"name":"Anne Lynn S. Chang","is_ca":false},{"name":"Michael R. Migden","is_ca":false},{"name":"Siyu Li","is_ca":false},{"name":"Suk‐Young Yoo","is_ca":false},{"name":"Kosalai Kal Mohan","is_ca":false},{"name":"Ebony Coates","is_ca":false},{"name":"Emmanuel Chiebuka Okoye","is_ca":false},{"name":"Jean‐François Baurain","is_ca":false},{"name":"Oliver Bechter","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Marcus O. Butler","is_ca":true},{"name":"Leonel F. Hernandez‐Aya","is_ca":false},{"name":"Lisa Licitra","is_ca":false},{"name":"Rogerio I. Neves","is_ca":false},{"name":"E.P. Yanez Ruiz","is_ca":false},{"name":"Frank Seebach","is_ca":false},{"name":"Israel Lowy","is_ca":false},{"name":"Timothy G. Bowler","is_ca":false},{"name":"Matthew G. Fury","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01888602988988578,"gpt":0.2952838839229059,"spread":0.2763978540330201,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006150085,0.0002274856,0.0007735722,0.0003000014,0.00005363309,0.000007473439,0.0002494901,0.00005698867,0.000009575705],"category_scores_gemma":[0.001069438,0.0001221478,0.0001420246,0.0006335467,0.0001354289,0.000003835395,0.00006716949,0.0001674897,3.410193e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005171678,"about_ca_system_score_gemma":0.000166703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001170155,"about_ca_topic_score_gemma":0.000171775,"domain_scores_codex":[0.9979855,0.0001965971,0.0008849313,0.0002464137,0.0004358201,0.0002507574],"domain_scores_gemma":[0.9977557,0.0002640203,0.0007232121,0.000347373,0.0007905083,0.0001191944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2353245,0.009366279,0.02883331,0.001263964,0.009653066,0.003553312,0.03061993,0.02600154,0.6168078,0.000005767344,0.02305401,0.0155165],"study_design_scores_gemma":[0.03162481,0.05408701,0.009028679,0.002062126,0.004398518,0.0002395073,0.007456611,0.000737257,0.8866415,0.0000175943,0.003126314,0.0005800503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974299,0.0005866867,0.0005488606,0.0007576163,0.0001564851,0.0003693122,0.00008987979,0.000001801916,0.00005947377],"genre_scores_gemma":[0.9988502,0.00004570146,0.0003995207,0.0003372983,0.0001598953,0.000007864739,0.00005575575,0.00002444673,0.000119326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2698337,"threshold_uncertainty_score":0.4981042,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309315772","doi":"10.25251/skin.6.6.5","title":"A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Internal medicine; Oncology; Risk assessment; Prospective cohort study; Population; Incidence (geometry); Personalized medicine; Intensive care medicine; Bioinformatics; Environmental health","authors":[{"name":"Eli Saleeby","is_ca":false},{"name":"Kenneth Bielinski","is_ca":true},{"name":"Alison L. Fitzgerald","is_ca":false},{"name":"Jennifer J. Siegel","is_ca":false},{"name":"Sherrif F. Ibrahim","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02762869602684959,"gpt":0.3193341928845215,"spread":0.2917054968576719,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004775194,0.0006653414,0.001734473,0.0002174634,0.001097114,0.00003139901,0.001057044,0.0001452525,0.00027334],"category_scores_gemma":[0.001783144,0.0003120871,0.0004002276,0.0004979901,0.001080228,0.00009169959,0.0006138242,0.002173835,0.000006223334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004235329,"about_ca_system_score_gemma":0.0004161123,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002249722,"about_ca_topic_score_gemma":0.0001758676,"domain_scores_codex":[0.9918867,0.001456054,0.00245288,0.0007599431,0.002602405,0.0008420607],"domain_scores_gemma":[0.9896222,0.005224824,0.002482268,0.001249198,0.0008937008,0.0005278014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01888262,0.009311493,0.9433275,0.0001627688,0.0006997507,0.002083116,0.002439822,0.00002986997,0.00002514867,6.629384e-7,0.01975029,0.003286925],"study_design_scores_gemma":[0.03936692,0.04810885,0.8879142,0.000326113,0.003733152,0.005545276,0.01197296,0.0002067074,0.0005504313,0.00006564434,0.001805219,0.0004045652],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986944,0.002031642,0.0002649211,0.001767221,0.001826233,0.006481153,0.0002180648,0.00004324475,0.0004235724],"genre_scores_gemma":[0.995483,0.0006181306,0.001456869,0.00078572,0.001004583,0.0001984949,0.00003452208,0.0001131692,0.0003054441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05541337,"threshold_uncertainty_score":0.9999331,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213252676","doi":"10.25251/skin.5.supp.37","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Placebo; Psoriasis; Medicine; Internal medicine; Pharmacology; Dermatology; Psoriatic arthritis; Alternative medicine; Pathology","authors":[{"name":"Diamant Thaçi","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Bruce Strober","is_ca":false},{"name":"Neil J. Korman","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Elizabeth Colston","is_ca":false},{"name":"Jonghyeon Kim","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Akimichi Morita","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0246529517252897,"gpt":0.2993854296567134,"spread":0.2747324779314237,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004501353,0.000518708,0.001762393,0.0002378377,0.000211832,0.00007086105,0.0002208085,0.0002068051,0.00005364347],"category_scores_gemma":[0.006710214,0.0002529219,0.00007984627,0.0008070828,0.0004184852,0.0001906147,0.00006462297,0.001176734,0.000002793908],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001687203,"about_ca_system_score_gemma":0.0006871087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002644749,"about_ca_topic_score_gemma":0.0009354929,"domain_scores_codex":[0.9943459,0.002339957,0.001551983,0.0004584101,0.0008284443,0.0004753178],"domain_scores_gemma":[0.9924342,0.004481523,0.0008431677,0.0005393377,0.001091935,0.00060986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5667415,0.002506216,0.004589205,0.0004151337,0.003171903,0.03013549,0.07827819,0.001478791,0.2146054,0.00006296755,0.06672315,0.03129201],"study_design_scores_gemma":[0.3760791,0.05101315,0.008789709,0.02496321,0.01021843,0.07604066,0.06673992,0.01436396,0.3364305,0.001555626,0.03071851,0.00308723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988728,0.003549179,0.0001552905,0.00573117,0.0004363708,0.001060049,0.0002291403,0.00002661159,0.00008415289],"genre_scores_gemma":[0.9943176,0.0007635617,0.000990579,0.002525251,0.001164652,0.00001444408,0.00007965272,0.00006409761,0.00008014496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1906625,"threshold_uncertainty_score":0.9999923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3104685239","doi":"10.25251/skin.4.supp.93","title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada); Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Roflumilast; Proof of concept; Medicine; Dermatology; Computer science; Internal medicine","authors":[{"name":"Melinda Gooderham","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Mark Lee","is_ca":false},{"name":"Steven Kempers","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Laura K. Ferris","is_ca":false},{"name":"Terry M. Jones","is_ca":false},{"name":"Étienne Saint‐Cyr Proulx","is_ca":true},{"name":"Robert Bissonnette","is_ca":true},{"name":"Neal Bhatia","is_ca":false},{"name":"Scott Guenthner","is_ca":false},{"name":"Robert A. Koppel","is_ca":false},{"name":"Howard G. Welgus","is_ca":false},{"name":"Charlotte Merritt","is_ca":false},{"name":"M.E.M. Elias","is_ca":false},{"name":"Lynn Navale","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Michael Droege","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01259036974305243,"gpt":0.2879166144450862,"spread":0.2753262447020338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004947384,0.000146631,0.0006945754,0.00007649316,0.00008769201,0.000004063179,0.000157618,0.00004700323,0.00005113156],"category_scores_gemma":[0.001395642,0.00007175846,0.00005273408,0.0001947715,0.0007555265,0.00004386463,0.0000525366,0.0003536115,3.481794e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001286617,"about_ca_system_score_gemma":0.0001060723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001533849,"about_ca_topic_score_gemma":0.00001763901,"domain_scores_codex":[0.9981578,0.000292089,0.0009142361,0.0001024441,0.0003723092,0.0001610963],"domain_scores_gemma":[0.9976612,0.001322875,0.0004992218,0.0001869155,0.0001474334,0.0001824056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04260702,0.01249408,0.2644275,0.002640834,0.004323949,0.0341649,0.2256245,0.0003731004,0.002681612,0.0003519867,0.06820927,0.3421013],"study_design_scores_gemma":[0.1406918,0.05916942,0.4389178,0.007214149,0.007870587,0.1969492,0.1015746,0.002183323,0.01853754,0.001751783,0.02431615,0.0008237127],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967896,0.01879467,0.00006745869,0.01225101,0.0001212446,0.0005521118,0.000004760187,0.000004699533,0.0003080183],"genre_scores_gemma":[0.9979668,0.001048462,0.00001759477,0.000758877,0.0001618097,0.000001246109,0.000001320561,0.00001090619,0.00003300629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3412776,"threshold_uncertainty_score":0.2926225,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388626054","doi":"10.25251/skin.7.supp.291","title":"Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Phase (matter); Dermatology; Medicine; Chemistry; Organic chemistry","authors":[{"name":"Brett King","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Christos Tziotzios","is_ca":false},{"name":"Lidia Rudnicka","is_ca":false},{"name":"P. Joly","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Rodney Sinclair","is_ca":false},{"name":"Susan D. Anway","is_ca":false},{"name":"Dalia Wajsbrot","is_ca":false},{"name":"Alexandre Lejeune","is_ca":false},{"name":"Samuel H. Zwillich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08132641213904793,"gpt":0.4348392751947991,"spread":0.3535128630557511,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001892457,0.0002138189,0.001238314,0.0002028649,0.0001234082,0.000007783135,0.0003008806,0.0001015335,0.0003313625],"category_scores_gemma":[0.001953745,0.00007728092,0.0005333757,0.0009542325,0.0007399565,0.00002446798,0.00002100968,0.0002604813,0.000001007825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003439566,"about_ca_system_score_gemma":0.0002225646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002355442,"about_ca_topic_score_gemma":0.0002915101,"domain_scores_codex":[0.9971915,0.0003154664,0.001527532,0.0001633017,0.0005644382,0.0002377183],"domain_scores_gemma":[0.9913949,0.006905908,0.000712804,0.0004786564,0.0003271211,0.0001805551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1996503,0.004082253,0.0009227951,0.0000301033,0.01056702,0.0002569529,0.005778976,0.00005050141,0.0004564434,0.00003213216,0.01589427,0.7622783],"study_design_scores_gemma":[0.3373157,0.09068259,0.001990881,0.0005295298,0.04830418,0.0006891079,0.02197047,0.01516143,0.0005040145,0.0004594802,0.4821549,0.0002376469],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825345,0.004352961,0.000769306,0.009232134,0.0004829945,0.001910394,0.0004469641,0.00001869814,0.0002520084],"genre_scores_gemma":[0.9830878,0.01446661,0.0002262489,0.0003765044,0.001276814,0.00002173877,0.0003064568,0.00002541228,0.0002124359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7620407,"threshold_uncertainty_score":0.3628187,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2993441120","doi":"10.25251/skin.3.6.2","title":"Transitioning Between Biologics","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Biologic Agents; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Disease","authors":[{"name":"Ronald Vender","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01464011930249902,"gpt":0.2405203201935189,"spread":0.2258802008910199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000602916,0.0001243321,0.0003700305,0.00008758895,0.0001005747,0.000002583811,0.0002485666,0.0001288869,0.001097739],"category_scores_gemma":[0.00006657048,0.00006002386,0.0000932572,0.0001083146,0.0001569863,0.00003234027,0.00001339079,0.0002588069,0.0002366906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002561882,"about_ca_system_score_gemma":0.00003354779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001437791,"about_ca_topic_score_gemma":0.000002493273,"domain_scores_codex":[0.9990299,0.0002717797,0.0003760884,0.00007359155,0.00006086957,0.000187823],"domain_scores_gemma":[0.9987538,0.0006861282,0.0002904873,0.0001594179,0.00008792554,0.0000222275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00255658,0.0002082233,0.04498101,0.00006277909,0.003541962,0.0004563006,0.01111779,0.0001784851,0.668529,0.0005346371,0.01438976,0.2534435],"study_design_scores_gemma":[0.02974515,0.02936945,0.07684063,0.002254219,0.009644493,0.1191672,0.01576097,0.0000135154,0.2822857,0.009504699,0.4238673,0.001546648],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878605,0.006510371,0.0001747356,0.001750062,0.001327727,0.0001137624,0.000008143099,0.00001227827,0.002242392],"genre_scores_gemma":[0.9973251,0.0005976714,0.00004015461,0.0001969885,0.0003378941,3.976998e-7,0.00001629494,0.00000880318,0.001476755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4094776,"threshold_uncertainty_score":0.9998154,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789068895","doi":"10.25251/skin.2.supp.4","title":"Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Term (time); Dermatology; Clinical efficacy; Internal medicine; Physics","authors":[{"name":"Kim Papp","is_ca":true},{"name":"Kristian Reich","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Rodney Sinclair","is_ca":false},{"name":"Stephen K. Tyring","is_ca":false},{"name":"N. Cichanowitz","is_ca":false},{"name":"Stuart A. Green","is_ca":false},{"name":"Qing Li","is_ca":false},{"name":"Carmen La Rosa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04899517628077045,"gpt":0.3759920803540572,"spread":0.3269969040732868,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008944496,0.0002644093,0.001179076,0.0001875252,0.00009591384,0.000003232544,0.0003338789,0.0002201917,0.000277026],"category_scores_gemma":[0.001452648,0.0001257012,0.0001780389,0.00025054,0.0008516892,0.0000458978,0.00006420112,0.000309073,0.00005918706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001819322,"about_ca_system_score_gemma":0.0002658611,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000116985,"about_ca_topic_score_gemma":0.0007730796,"domain_scores_codex":[0.9967325,0.0008172934,0.001709497,0.0002844732,0.0001470299,0.0003091459],"domain_scores_gemma":[0.9938099,0.004327535,0.0009439155,0.0005066241,0.0003212043,0.00009079792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1986284,0.005690766,0.1077111,0.00001468169,0.007369402,0.001293599,0.008446081,0.00002046461,0.0009259249,0.00000429537,0.007372333,0.662523],"study_design_scores_gemma":[0.1046306,0.09475704,0.7885587,0.001573718,0.003000977,0.0006728654,0.0003649663,0.000001853526,0.001116385,0.00002727626,0.005016869,0.0002786579],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994094,0.002857398,0.000009101562,0.0003531095,0.002096909,0.0004346944,0.0001194344,0.000009256863,0.00002615041],"genre_scores_gemma":[0.994324,0.004112081,0.00008837949,0.0001330917,0.0009420916,0.000002224726,0.00004936464,0.00002328174,0.0003254717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6808477,"threshold_uncertainty_score":0.5125945,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3103727622","doi":"10.25251/skin.4.supp.83","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Double blinded; Medicine; Randomized controlled trial; Placebo; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Peter Foley","is_ca":false},{"name":"JG Krueger","is_ca":false},{"name":"Andreas Pinter","is_ca":false},{"name":"Kristian Reich","is_ca":false},{"name":"Ronald Vender","is_ca":true},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Cindy Madden","is_ca":false},{"name":"Luke Peterson","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01612960875211718,"gpt":0.2519932776894991,"spread":0.235863668937382,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002414402,0.0004993215,0.003712914,0.0002693876,0.0001505884,0.00001506969,0.0003541936,0.0001679137,0.00007327519],"category_scores_gemma":[0.0009585858,0.0002225247,0.000173052,0.000341233,0.0005073912,0.00009598711,0.00005668477,0.0004993076,0.000004703052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005387553,"about_ca_system_score_gemma":0.0001910886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000478766,"about_ca_topic_score_gemma":0.0002201681,"domain_scores_codex":[0.9946034,0.002440937,0.001889665,0.0003714657,0.0003408316,0.0003536854],"domain_scores_gemma":[0.9922407,0.005374141,0.001518222,0.0003426424,0.0003802566,0.0001440818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653864,0.001688792,0.0001030141,0.00001221163,0.007073859,0.0003067539,0.02179032,0.000941129,0.0002174047,0.000009593879,0.0002451829,0.00222537],"study_design_scores_gemma":[0.975984,0.01415357,0.00008790965,0.0004447607,0.005724695,0.0004385614,0.00228731,0.00005449407,0.0005009716,0.00002788509,0.00005166679,0.0002441668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891524,0.001423657,0.0002223981,0.002610014,0.0002448216,0.006031259,0.000116174,0.00001720765,0.0001820288],"genre_scores_gemma":[0.9988465,0.000325641,0.0001556113,0.0002574671,0.0001505197,0.00005313452,0.00007827565,0.00003745696,0.00009544214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01950301,"threshold_uncertainty_score":0.9074293,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4229034592","doi":"10.25251/skin.6.supp.4","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Pharmacology; Dermatology","authors":[{"name":"Richard B. Warren","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Bruce Strober","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Howard Sofen","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Neil J. Korman","is_ca":false},{"name":"Min Zheng","is_ca":false},{"name":"Elizabeth Colston","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Sundeep Kundu","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04009431060346913,"gpt":0.302258072534325,"spread":0.2621637619308559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004356343,0.0004063609,0.00117653,0.0002626676,0.0006476456,0.00002730973,0.0005861344,0.000173298,0.0003226339],"category_scores_gemma":[0.001939571,0.0002206062,0.0001459795,0.0005127887,0.0002471565,0.0001142936,0.0001432318,0.000908244,0.0000151881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001697315,"about_ca_system_score_gemma":0.0002427586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008022597,"about_ca_topic_score_gemma":0.0004651153,"domain_scores_codex":[0.9931063,0.004324828,0.001458792,0.0003834596,0.000255963,0.0004706522],"domain_scores_gemma":[0.9937964,0.004494668,0.0009225261,0.0004651191,0.0001984817,0.0001228115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3042119,0.005311353,0.0003031808,0.0000236961,0.003779644,0.003801946,0.07836991,0.003346244,0.2987708,0.0001625123,0.1008008,0.2011179],"study_design_scores_gemma":[0.3430208,0.08532566,0.004715336,0.001957677,0.01015873,0.07143686,0.05474647,0.0002951007,0.2231353,0.007618408,0.1947579,0.002831766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787339,0.009517833,0.00003719017,0.008610722,0.001462339,0.0007931612,0.000682736,0.00002449116,0.0001376037],"genre_scores_gemma":[0.996147,0.001196993,0.0001015187,0.001195563,0.0006737713,0.00002345427,0.0001947079,0.00003964489,0.0004273051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1982862,"threshold_uncertainty_score":0.8996059,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989489239","doi":"10.25251/skin.3.supp.17","title":"Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Phase (matter); Medicine; Physics","authors":[{"name":"C.E.M. Griffiths","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Mengsa Song","is_ca":false},{"name":"Megan Miller","is_ca":false},{"name":"Yin You","is_ca":false},{"name":"Y-K Shen","is_ca":false},{"name":"Chenglong Han","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01294236937267002,"gpt":0.3188810422485794,"spread":0.3059386728759094,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007553619,0.000160194,0.0007059192,0.0001038084,0.00003718889,0.000004179858,0.0002164972,0.00004598068,0.0001395682],"category_scores_gemma":[0.0008157492,0.00006499343,0.0001178393,0.0002419567,0.0001996354,0.00003206071,0.00001574306,0.0001631634,0.00000852434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001561424,"about_ca_system_score_gemma":0.0003944877,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005181911,"about_ca_topic_score_gemma":0.00005468385,"domain_scores_codex":[0.9981141,0.0002156545,0.0007842529,0.000130277,0.0005760882,0.0001795987],"domain_scores_gemma":[0.9961297,0.002011724,0.0008455559,0.0005344657,0.0003533236,0.0001252353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9307609,0.0005884434,0.0002081722,0.0000148744,0.001506104,0.0008352582,0.02953941,0.000129094,0.01380245,0.00002347233,0.007817005,0.01477478],"study_design_scores_gemma":[0.6775671,0.1745369,0.005900508,0.004612174,0.008231238,0.008448963,0.02137962,0.00005839637,0.01403664,0.0002175166,0.08470988,0.0003010487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898077,0.0007022126,0.00005659308,0.007062837,0.0005330846,0.001054104,0.0001451601,0.000005589872,0.0006327235],"genre_scores_gemma":[0.9944867,0.0002641188,0.0001810963,0.0003509066,0.0003716408,0.000003960178,0.00001131455,0.00002232844,0.004307965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2531938,"threshold_uncertainty_score":0.2650355,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213919372","doi":"10.25251/skin.5.supp.44","title":"Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Roflumilast; Open label; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Adverse effect; Term (time); Pharmacology; Internal medicine; COPD","authors":[{"name":"Linda Stein Gold","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Kim Papp","is_ca":true},{"name":"Laura K. Ferris","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"David N. Adam","is_ca":true},{"name":"Javier Alonso‐Llamazares","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Steve Kempers","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Wei Jing Loo","is_ca":false},{"name":"Daniel Stewart","is_ca":false},{"name":"Walter K. Nahm","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Lynn Navale","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0163068083733599,"gpt":0.2737719592662977,"spread":0.2574651508929378,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005917135,0.0002877932,0.000917707,0.0001430706,0.0001350032,0.00001169566,0.0004642777,0.0001463043,0.0001596516],"category_scores_gemma":[0.0004926518,0.0001612264,0.0000448778,0.0002767855,0.0002698936,0.00008639043,0.0001388604,0.0004019852,0.000006993916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000107568,"about_ca_system_score_gemma":0.0002444647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003960105,"about_ca_topic_score_gemma":0.001677802,"domain_scores_codex":[0.9973884,0.0007631453,0.001097306,0.000282442,0.0001779317,0.0002907939],"domain_scores_gemma":[0.9970258,0.001262745,0.0008554508,0.0004333555,0.0003588157,0.00006383927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3658516,0.09209711,0.1286221,0.0001377839,0.01127908,0.008752147,0.04234994,0.00009084347,0.04476564,0.00003494765,0.002067009,0.3039518],"study_design_scores_gemma":[0.5257033,0.06829153,0.3681408,0.003745344,0.004566031,0.005091564,0.004533827,0.000007167312,0.01847883,0.00004811021,0.0008010824,0.0005925102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922245,0.005741549,0.00001441893,0.0004693222,0.0005923253,0.0006192983,0.0001689769,0.00000619148,0.0001633965],"genre_scores_gemma":[0.9969332,0.002335176,0.0000345497,0.00006745131,0.0001633013,0.00000382051,0.0001626489,0.00002322227,0.0002766915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3033593,"threshold_uncertainty_score":0.657462,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2986283446","doi":"10.25251/skin.3.supp.38","title":"Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Nail (fastener); Dermatology; Outcome (game theory); Internal medicine; Infliximab; Tumor necrosis factor alpha; Materials science","authors":[{"name":"Alice B. Gottlieb","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"C. Leonardi","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Marion Boehnlein","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03094004696178332,"gpt":0.2977013145001826,"spread":0.2667612675383993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009442305,0.0003326475,0.001292304,0.0002596913,0.00009342669,0.00001206384,0.000459378,0.0001991226,0.0006756787],"category_scores_gemma":[0.0006037958,0.0001634316,0.000132319,0.000220489,0.00008121947,0.00008934942,0.0000470453,0.0004267138,0.0001841949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001321701,"about_ca_system_score_gemma":0.0001350416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005118183,"about_ca_topic_score_gemma":0.0002536135,"domain_scores_codex":[0.9967054,0.0008839889,0.001554163,0.0002607467,0.0001988721,0.0003968205],"domain_scores_gemma":[0.99669,0.001599075,0.001014821,0.0004507153,0.0001660848,0.00007930567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4577616,0.001939892,0.003361454,0.00007523,0.006414649,0.008692917,0.0293253,0.001196525,0.2763993,0.00005803592,0.01784167,0.1969334],"study_design_scores_gemma":[0.5484016,0.05219344,0.003226383,0.00469904,0.008350138,0.1147299,0.01723202,0.000148917,0.1858414,0.002467755,0.06023131,0.002478103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893681,0.001623206,0.00006977749,0.005178492,0.002111797,0.0007520156,0.0002266397,0.00001505536,0.000654929],"genre_scores_gemma":[0.9957656,0.0003258185,0.0001043579,0.0002996592,0.0003481475,0.000007615065,0.00006888507,0.00002897068,0.003050922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1944553,"threshold_uncertainty_score":0.7398207,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213641793","doi":"10.25251/skin.5.supp.62","title":"Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Dermatology","authors":[{"name":"Lawrence Eichenfeld","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Robert Bissonnette","is_ca":true},{"name":"Anna M. Tallman","is_ca":false},{"name":"David S. Rubenstein","is_ca":false},{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"John E Jett","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0176862136550827,"gpt":0.3443466066119262,"spread":0.3266603929568435,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004718131,0.0001627919,0.0006389063,0.00005683877,0.000133604,0.000009583782,0.0001745943,0.0000610242,0.00003483427],"category_scores_gemma":[0.0007080311,0.00006828518,0.0001540334,0.0001645724,0.0003459115,0.00003917206,0.00002910444,0.000243171,8.280334e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003784441,"about_ca_system_score_gemma":0.0001792433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003952355,"about_ca_topic_score_gemma":0.00005997483,"domain_scores_codex":[0.998309,0.0002453057,0.0008164642,0.0001360196,0.0002784028,0.0002147694],"domain_scores_gemma":[0.997379,0.001610334,0.0003232873,0.0003059462,0.0002330014,0.0001484363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01356079,0.008178055,0.1245061,0.0003128587,0.00268009,0.004753709,0.01662281,0.0005656708,0.0001423081,0.00009467689,0.01723205,0.8113508],"study_design_scores_gemma":[0.07536919,0.04388746,0.4416094,0.006945523,0.006810724,0.3727321,0.01619102,0.00681327,0.003294562,0.00161186,0.02415807,0.0005768041],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9654814,0.0168783,0.0001574156,0.01614838,0.0002161966,0.001004981,0.00001635433,0.000007377231,0.00008960252],"genre_scores_gemma":[0.990539,0.007272467,0.0002809019,0.00127269,0.0004573113,0.00002340387,0.000007568445,0.00001384679,0.0001328377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.810774,"threshold_uncertainty_score":0.2784589,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","authors":[{"name":"Kristian Reich","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"April W. Armstrong","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"J.F. Merola","is_ca":false},{"name":"Cindy Madden","is_ca":false},{"name":"M Wang","is_ca":false},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01981299134265906,"gpt":0.255535521771845,"spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255164,0.0003545296,0.001921615,0.0002142652,0.0001306043,0.00001202415,0.0002494889,0.0001465956,0.00005854788],"category_scores_gemma":[0.0006286766,0.0001803056,0.00008616728,0.0002388014,0.0002541456,0.00007756795,0.00006957525,0.000376739,0.000005131268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003970085,"about_ca_system_score_gemma":0.00009387828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002217814,"about_ca_topic_score_gemma":0.0001453554,"domain_scores_codex":[0.996741,0.001140225,0.001334286,0.000296803,0.0002151693,0.0002725485],"domain_scores_gemma":[0.9956234,0.002913432,0.0008903405,0.0002447443,0.0002081436,0.0001199032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9652251,0.001073356,0.0003466573,0.00001190539,0.002626725,0.0001862317,0.022668,0.0003423696,0.0005388965,0.000003697474,0.0002660111,0.006711028],"study_design_scores_gemma":[0.981768,0.0102734,0.0007234898,0.0003167861,0.002594713,0.0004092016,0.002915128,0.00004493076,0.0006080171,0.00003118023,0.0001253077,0.0001898947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924064,0.001802625,0.00006381857,0.0023973,0.0002520446,0.002833629,0.0001435841,0.00001033965,0.00009023092],"genre_scores_gemma":[0.9989914,0.0004572872,0.00006916904,0.0002418134,0.0001135449,0.00001638755,0.00003467835,0.0000238003,0.00005193898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01975287,"threshold_uncertainty_score":0.7352648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3119812808","doi":"10.25251/skin.5.supp.15","title":"Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Medicine; Adalimumab; Plaque psoriasis; Double blinded; Multicenter study; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Pathology; Placebo; Alternative medicine","authors":[{"name":"Richard B. Warren","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Jerry Bagel","is_ca":false},{"name":"KA Papp","is_ca":true},{"name":"Paul S. Yamauchi","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Dirk De Cuyper","is_ca":false},{"name":"Luke Peterson","is_ca":false},{"name":"Nancy Cross","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02438267293933946,"gpt":0.2821770173124763,"spread":0.2577943443731369,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001051827,0.0003949821,0.001995478,0.0002131031,0.0001886487,0.00002056044,0.0002505169,0.0002149399,0.0001381649],"category_scores_gemma":[0.0009052262,0.000209548,0.0001672389,0.0002579486,0.0002268862,0.00009579289,0.00005358492,0.0004848982,0.000009361826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001412228,"about_ca_system_score_gemma":0.0002567686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00024376,"about_ca_topic_score_gemma":0.0003935746,"domain_scores_codex":[0.9959202,0.001822016,0.00131818,0.0003270335,0.0002453655,0.00036724],"domain_scores_gemma":[0.9929818,0.005235908,0.000892191,0.0003465213,0.000433754,0.0001098115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9822502,0.001356174,0.00001348236,0.000004575444,0.003889935,0.0003510431,0.005616577,0.0003315484,0.0006247316,0.000009238737,0.0003727782,0.005179698],"study_design_scores_gemma":[0.98716,0.004643722,0.0001339493,0.000329196,0.00243525,0.0003583305,0.001038127,0.00003256128,0.003218076,0.00002149828,0.0004102019,0.0002190669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917649,0.002090025,0.00005248867,0.00150737,0.002051014,0.002128485,0.0002029833,0.00001291998,0.0001898023],"genre_scores_gemma":[0.9985331,0.0005756876,0.00008278493,0.000156014,0.0002737205,0.00002077482,0.0001862478,0.00002493156,0.0001467703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006768156,"threshold_uncertainty_score":0.8545119,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3214549902","doi":"10.25251/skin.5.supp.38","title":"Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Domain (mathematical analysis); Dermatology; Mathematics; Mathematical analysis","authors":[{"name":"April W. Armstrong","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Joe Zhuo","is_ca":false},{"name":"Brandon Becker","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Jonghyeon Kim","is_ca":false},{"name":"Kim Papp","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01256961024483013,"gpt":0.2492058804157619,"spread":0.2366362701709317,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009594306,0.0004116403,0.0008657809,0.0001410777,0.0003575074,0.00002825924,0.0002932036,0.0001805812,0.00003364628],"category_scores_gemma":[0.0007894906,0.0001983731,0.00007217818,0.000277087,0.0004886913,0.0001193113,0.0001375328,0.0004460382,0.000005362914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006953942,"about_ca_system_score_gemma":0.0001237983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001666461,"about_ca_topic_score_gemma":0.0005121833,"domain_scores_codex":[0.9971234,0.001029314,0.0008471038,0.0003724025,0.0002084874,0.0004192675],"domain_scores_gemma":[0.9957091,0.002950677,0.0005125427,0.0003969019,0.0003330229,0.00009778814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2118827,0.00315097,0.04568165,0.000215291,0.0222488,0.005128264,0.1850503,0.0002971019,0.1052373,0.0004291302,0.02378061,0.3968979],"study_design_scores_gemma":[0.3938657,0.05748229,0.1939192,0.01352458,0.01692885,0.03465561,0.149484,0.00005757867,0.0917818,0.02191124,0.02175646,0.004632632],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9680009,0.02527888,0.0000331946,0.00514745,0.0007293741,0.0004281066,0.0002931571,0.00001381858,0.00007507443],"genre_scores_gemma":[0.9929716,0.005358116,0.000215775,0.0007959519,0.0003072013,0.00001105622,0.00008419715,0.00003203387,0.0002240804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3922653,"threshold_uncertainty_score":0.8089421,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","authors":[{"name":"Christopher J. Sayed","is_ca":false},{"name":"Vivian Y. Shi","is_ca":false},{"name":"Jennifer L. Hsiao","is_ca":false},{"name":"Georgios Kokolakis","is_ca":false},{"name":"Brian Kirby","is_ca":false},{"name":"Vincent Piguet","is_ca":true},{"name":"Leah Davis","is_ca":false},{"name":"Muhammad Bari","is_ca":false},{"name":"Cynthia Madden","is_ca":false},{"name":"Sarah Knowles","is_ca":false},{"name":"Errol P. Prens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05229412364784481,"gpt":0.3412784765418269,"spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004901931,0.000596698,0.002913124,0.000264247,0.0002817806,0.00009817327,0.0004206743,0.0001418142,0.0004660923],"category_scores_gemma":[0.001404958,0.0002135785,0.00022523,0.0003260069,0.000388696,0.0002399924,0.0001231003,0.0005555056,0.00001917428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002543811,"about_ca_system_score_gemma":0.0002886916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004021661,"about_ca_topic_score_gemma":0.0001493362,"domain_scores_codex":[0.9947814,0.001675506,0.001761363,0.0004844357,0.0008457371,0.000451602],"domain_scores_gemma":[0.9912418,0.006922727,0.0005970751,0.000678317,0.0002030374,0.0003570582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9595632,0.00190823,0.00017622,0.00002142958,0.004219058,0.01199103,0.007205081,0.000007542435,0.0002728577,0.000004501605,0.00592301,0.008707833],"study_design_scores_gemma":[0.9503853,0.01054291,0.00003270635,0.001357452,0.007118355,0.02620051,0.0009210498,0.0008642299,0.0002863427,0.00005731809,0.001985789,0.0002480912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8927701,0.006604806,0.0001481762,0.09166296,0.0004811711,0.007621006,0.0005740927,0.00002879348,0.0001089703],"genre_scores_gemma":[0.9960455,0.001327644,0.0001929951,0.0002297919,0.0005362261,0.00008508882,0.0004991328,0.00005706412,0.001026571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1032755,"threshold_uncertainty_score":0.870948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406295719","doi":"10.25251/skin.9.supp.510","title":"Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Term (time); Dermatology; Medicine; Physics","authors":[{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Alan D. Irvine","is_ca":false},{"name":"Eric L. Simpson","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Stephan Weidinger","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Heidi M. Crane","is_ca":false},{"name":"Hany Elmaraghy","is_ca":false},{"name":"Louise DeLuca-Carter","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Chaoran Hu","is_ca":false},{"name":"Evangeline Pierce","is_ca":false},{"name":"Helena Agell","is_ca":false},{"name":"Diamant Thaçi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00559892539955492,"gpt":0.2477296975346066,"spread":0.2421307721350517,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002406044,0.0001741529,0.0006798008,0.0003035036,0.0000486236,0.000006011586,0.000195021,0.00007385985,0.00008716519],"category_scores_gemma":[0.0005631765,0.0001054408,0.00004266031,0.0003135685,0.0001660608,0.00004563874,0.00006054264,0.0002879413,0.000004686405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007437274,"about_ca_system_score_gemma":0.00016531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006160625,"about_ca_topic_score_gemma":0.00006898439,"domain_scores_codex":[0.9982632,0.0001450663,0.0008016414,0.0001605813,0.0004155646,0.0002139499],"domain_scores_gemma":[0.998481,0.0004935852,0.0002675004,0.0003144138,0.0002347353,0.000208788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1313258,0.0008545219,0.7442526,0.0004633893,0.001404501,0.00610201,0.01984795,0.0006106823,0.0001151844,0.00006538408,0.06623289,0.02872509],"study_design_scores_gemma":[0.01693902,0.0009905697,0.9754304,0.003679323,0.0003934004,0.001291136,0.0003733204,0.00002550741,0.0001977131,0.0002389651,0.0003382293,0.0001024482],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894182,0.0007971193,0.0001817932,0.008440781,0.0001980484,0.0005141815,0.00003699556,0.000007217621,0.00040567],"genre_scores_gemma":[0.9955599,0.0001626919,0.00013527,0.003740806,0.00006399951,0.000001641377,0.00001647979,0.00001347918,0.000305673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2311777,"threshold_uncertainty_score":0.429975,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3212995571","doi":"10.25251/skin.5.supp.35","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Extension (predicate logic); Aryl hydrocarbon receptor; Aryl; Psoriasis; Hydrocarbon; Medicine; Combinatorial chemistry; Pharmacology; Chemistry; Computer science; Dermatology; Organic chemistry; Physics; Biochemistry","authors":[{"name":"Bruce Strober","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Robert Bissonnette","is_ca":true},{"name":"April W. Armstrong","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Philip Brown","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Anna M. Tallman","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03423787189915257,"gpt":0.2839932816325126,"spread":0.24975540973336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009608095,0.000269786,0.000809952,0.0001289644,0.0001839257,0.000006155024,0.0003099544,0.0002247262,0.0001723606],"category_scores_gemma":[0.0004682493,0.0001615102,0.0002811085,0.0001880678,0.0002017115,0.00005404105,0.00004734695,0.0002968708,0.000005285599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008018492,"about_ca_system_score_gemma":0.0001802061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002392506,"about_ca_topic_score_gemma":0.00001633775,"domain_scores_codex":[0.9979897,0.0003023715,0.0009870478,0.0002179437,0.0001794685,0.0003234304],"domain_scores_gemma":[0.996882,0.001279432,0.001047535,0.000384037,0.0003582297,0.00004872081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04258986,0.001018195,0.0001402061,0.00006092733,0.001386079,0.0001406246,0.002174323,0.0001757508,0.9006718,0.00005658485,0.0005811588,0.05100446],"study_design_scores_gemma":[0.2100461,0.02811305,0.002823108,0.004145822,0.007315277,0.03222312,0.004041005,0.0002836724,0.7043846,0.0009623784,0.004832165,0.000829626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752696,0.01719734,0.00175599,0.001364461,0.003757588,0.0005105709,0.00002194995,0.00001369016,0.0001087947],"genre_scores_gemma":[0.9952649,0.002625237,0.0003104121,0.000195213,0.0008335171,0.00001034783,0.00004606404,0.00003249851,0.0006817945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1962872,"threshold_uncertainty_score":0.6586194,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3214388010","doi":"10.25251/skin.5.supp.41","title":"Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Dermis; Plaque psoriasis; Medicine; Roflumilast; Psoriasis; Dermatology; Pathology; Internal medicine","authors":[{"name":"Melinda Gooderham","is_ca":true},{"name":"Javier Alonso‐Llamazares","is_ca":false},{"name":"Jerry Bagel","is_ca":false},{"name":"John Browning","is_ca":false},{"name":"Zoe Draelos","is_ca":false},{"name":"Kimberly Grande","is_ca":false},{"name":"Adelaide A Herbert","is_ca":false},{"name":"Wei Jing Loo","is_ca":true},{"name":"Chih-ho Hong","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"Walter K. Nahm","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"David M. Pariser","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Irina Turchin","is_ca":true},{"name":"Amy Feng","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0105701159799711,"gpt":0.3020733013765192,"spread":0.2915031853965481,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009573,0.0002708505,0.0008475371,0.0001361818,0.0001155142,0.00001184615,0.0002392136,0.00006849006,0.00005061846],"category_scores_gemma":[0.001487098,0.0001046185,0.0000899973,0.0004148948,0.0007419866,0.00007261689,0.00008328423,0.0006043425,2.670275e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002119586,"about_ca_system_score_gemma":0.0005526996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003031894,"about_ca_topic_score_gemma":0.0004130022,"domain_scores_codex":[0.9977002,0.0004263754,0.0007787068,0.0001703785,0.0006173378,0.0003070715],"domain_scores_gemma":[0.9970554,0.001396818,0.0005703106,0.0004268688,0.000445078,0.0001055481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03291373,0.007428116,0.7628512,0.001635799,0.004890181,0.0091471,0.07760988,0.0003514619,0.007481475,0.00002495238,0.007599615,0.08806647],"study_design_scores_gemma":[0.03069431,0.01122394,0.9012461,0.00328959,0.002004292,0.03058534,0.01850553,0.0003571878,0.001088325,0.0003682168,0.0003571523,0.0002800683],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9688786,0.02614879,0.000008367689,0.004262208,0.00008772518,0.0005409838,0.00001054729,0.000004228362,0.00005857837],"genre_scores_gemma":[0.9945564,0.004788306,0.00002481399,0.0003819947,0.000178301,0.00000508828,0.000004639669,0.0000238983,0.00003651072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1383948,"threshold_uncertainty_score":0.4266221,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","authors":[{"name":"Christos C. Zouboulis","is_ca":false},{"name":"Amit Garg","is_ca":false},{"name":"Christopher J. Sayed","is_ca":false},{"name":"Gregor B. E. Jemec","is_ca":false},{"name":"Georgios Kokolakis","is_ca":false},{"name":"John R Ingram","is_ca":false},{"name":"Akimichi Morita","is_ca":false},{"name":"Pratiksha Dokhe","is_ca":false},{"name":"Ingrid Pansar","is_ca":false},{"name":"Robert Rolleri","is_ca":false},{"name":"Christina Crater","is_ca":false},{"name":"Asim Datye","is_ca":true},{"name":"Alexa B. Kimball","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07663420508063443,"gpt":0.3691144696220155,"spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003631529,0.0003776321,0.001360681,0.0001535204,0.0002886136,0.00009120027,0.0002719563,0.0001317682,0.0001935136],"category_scores_gemma":[0.00183179,0.0001658217,0.00006289746,0.0004130361,0.0005439027,0.0003248505,0.0001553332,0.0007828069,0.000005772798],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001404267,"about_ca_system_score_gemma":0.000234261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005836948,"about_ca_topic_score_gemma":0.0001427693,"domain_scores_codex":[0.9960874,0.0008382938,0.001376248,0.000381751,0.0009684598,0.0003478145],"domain_scores_gemma":[0.9946439,0.003978253,0.0004696708,0.000470455,0.0001951941,0.0002424883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"case_report","study_design_scores_codex":[0.255284,0.006577853,0.002525723,0.0002168841,0.005028888,0.1963061,0.1540296,0.000008261968,0.006868894,0.0002041504,0.124792,0.2481577],"study_design_scores_gemma":[0.3179425,0.05008887,0.02088242,0.0166504,0.006452021,0.4376811,0.006598102,0.0001398757,0.0006670238,0.001688484,0.1402499,0.0009593783],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.849655,0.006902101,0.00003546671,0.1409672,0.0004156545,0.001448925,0.0002816867,0.00001902905,0.0002749367],"genre_scores_gemma":[0.9943468,0.003352648,0.0005848855,0.0003419117,0.0005143434,0.000005061554,0.0001469528,0.00005443468,0.0006529384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2471983,"threshold_uncertainty_score":0.6762012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392906202","doi":"10.25251/skin.8.supp.375","title":"Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Clinical trial; Medicine; Dermatology; Internal medicine","authors":[{"name":"Kristian Reich","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Juan Francisco Silvestre","is_ca":false},{"name":"D. Staumont‐Sallé","is_ca":false},{"name":"Antonio Costanzo","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"Amy S. Paller","is_ca":false},{"name":"Norito Katoh","is_ca":false},{"name":"Andreas Wollenberg","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Christian Bjerregård Øland","is_ca":false},{"name":"Ann‐Marie Tindberg","is_ca":false},{"name":"Le Gjerum","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03268452212128633,"gpt":0.3645907165020806,"spread":0.3319061943807943,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001080119,0.0001666566,0.00193047,0.0005028905,0.0000197052,0.000002014615,0.0001714864,0.00008246405,0.000211194],"category_scores_gemma":[0.0005113094,0.00006848619,0.0004387621,0.0008137417,0.0003433434,0.0000354661,0.000006357317,0.0001071191,3.362645e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009646735,"about_ca_system_score_gemma":0.0002717994,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001416128,"about_ca_topic_score_gemma":0.0001475724,"domain_scores_codex":[0.9966704,0.0006111715,0.002115054,0.0001197081,0.0003445842,0.000139116],"domain_scores_gemma":[0.9954492,0.002839268,0.0008856801,0.0003404969,0.0003709945,0.000114314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07538848,0.008453825,0.4715613,0.0006401762,0.06418927,0.001156143,0.03749969,0.002474214,0.0005096353,0.0001913712,0.007057489,0.3308784],"study_design_scores_gemma":[0.04056698,0.06420863,0.7881528,0.003005116,0.07674833,0.001158465,0.004639857,0.003081429,0.005762851,0.000305276,0.01209752,0.0002728083],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952214,0.00239105,0.0002282165,0.0008681759,0.0002404652,0.0007958097,0.0002160088,0.000003715451,0.00003514775],"genre_scores_gemma":[0.9980596,0.001510999,0.0001005337,0.00007176903,0.00006252599,0.000004889767,0.00009684266,0.00001358044,0.00007924216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3306056,"threshold_uncertainty_score":0.2792786,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392928302","doi":"10.25251/skin.8.supp.361","title":"Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Regeneron Pharmaceuticals; Meiji Seika Pharma; Eli Lilly and Company; Bristol-Myers Squibb; LEO Pharma; Incyte; Amgen","keywords":"Placebo; Psoriasis; Dermatology Life Quality Index; Medicine; Generalized pustular psoriasis; Quality of life (healthcare); Placebo group; Index (typography); Physical therapy; Dermatology; Alternative medicine; Pathology","authors":[{"name":"Bruce Strober","is_ca":false},{"name":"Arash Mostaghimi","is_ca":false},{"name":"Milan J. Anadkat","is_ca":false},{"name":"Christian Thoma","is_ca":false},{"name":"Ming Tang","is_ca":true},{"name":"Jason R. Guercio","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03282687181193359,"gpt":0.2558931768416337,"spread":0.2230663050297001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00560441,0.0002445715,0.0008153479,0.000139909,0.0001273264,0.00001004953,0.0005097691,0.0002158209,0.00006789969],"category_scores_gemma":[0.003229278,0.0001009588,0.0001970613,0.0003463987,0.0005475969,0.00004293547,0.00008151695,0.0004616589,0.000002060606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005193745,"about_ca_system_score_gemma":0.0001490457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002478137,"about_ca_topic_score_gemma":0.0007700765,"domain_scores_codex":[0.9941201,0.003781148,0.001417264,0.0001907972,0.0002533152,0.0002373681],"domain_scores_gemma":[0.9922758,0.006297177,0.0008269866,0.0004259263,0.0001368744,0.0000371719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5475665,0.0009170436,0.0350294,0.0003416088,0.01169317,0.0003303261,0.04091898,0.0008132154,0.2931792,0.0006566895,0.009940256,0.05861371],"study_design_scores_gemma":[0.6207495,0.01265041,0.1744019,0.01647277,0.01284182,0.004451707,0.0207355,0.000556871,0.1172417,0.006868624,0.0113742,0.001655027],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9584212,0.03705466,0.00003008025,0.002093218,0.001757129,0.0004731951,0.00007730797,0.0000109022,0.00008231396],"genre_scores_gemma":[0.9969479,0.002291315,0.00001110988,0.0001364088,0.0004371744,0.000005060675,0.00001617438,0.00001798182,0.0001368804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1759375,"threshold_uncertainty_score":0.4116982,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990965204","doi":"10.25251/skin.3.6.20","title":"Reply: Terra Firma-Forme Dermatosis, Keratotic Form","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Dermatology; Medicine; Art","authors":[{"name":"Daniel J. Callaghan","is_ca":true},{"name":"Kenneth A. Arndt","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004164474139625888,"gpt":0.2242680610396761,"spread":0.2201035869000502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003775605,0.0001772896,0.0002764926,0.00005893951,0.00007674177,0.000009852835,0.0004376751,0.00008782949,0.0004306735],"category_scores_gemma":[0.0001639723,0.00009654615,0.0001361002,0.00009070931,0.0001480517,0.000004585293,0.00007578949,0.0001896148,0.00003702614],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000191407,"about_ca_system_score_gemma":0.0001372502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001099218,"about_ca_topic_score_gemma":0.000004144424,"domain_scores_codex":[0.9986572,0.0000797844,0.0004910977,0.0001335437,0.0003750011,0.0002633209],"domain_scores_gemma":[0.9987953,0.0000564402,0.0003545988,0.0004470261,0.0001851628,0.0001614719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002455491,0.0003551218,0.0194026,0.0003252476,0.001121803,0.0006915723,0.002569663,0.0009892797,0.4350336,0.00008034356,0.5155079,0.02146735],"study_design_scores_gemma":[0.006577634,0.007706863,0.01187527,0.0008868141,0.0009904853,0.09909459,0.003989005,0.0002891062,0.120269,0.001730524,0.7456688,0.0009219547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837648,0.006608251,0.0003161517,0.003398573,0.0008597992,0.0002183971,0.000004353914,0.000005649078,0.004824076],"genre_scores_gemma":[0.9928219,0.001470488,0.000112118,0.003223629,0.0008410271,0.000001124737,0.00001158729,0.00002470546,0.00149347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3147647,"threshold_uncertainty_score":0.4715573,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388625689","doi":"10.25251/skin.7.supp.272","title":"Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dermatology; Atopic dermatitis; Adverse effect; Placebo; Head and neck; Erythema; Surgery; Internal medicine; Pathology; Alternative medicine","authors":[{"name":"Jenny E. Murase","is_ca":false},{"name":"Mónica Munera‐Campos","is_ca":false},{"name":"Hwanhee Hong","is_ca":true},{"name":"Alain Taı̈eb","is_ca":false},{"name":"Wen‐Hung Chung","is_ca":false},{"name":"Amber Reck Atwater","is_ca":false},{"name":"María José Rueda","is_ca":false},{"name":"Jinglin Zhong","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Ignasi Pau‐Charles","is_ca":false},{"name":"Mette Deleuran","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01124778858614377,"gpt":0.2637996245793265,"spread":0.2525518359931828,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001759013,0.0002265986,0.0007723037,0.0003613745,0.00007218796,0.000001565392,0.000130285,0.00005711525,0.0001696857],"category_scores_gemma":[0.0003259412,0.0001246142,0.00007056845,0.0004084062,0.0001812621,0.00005569983,0.00004486118,0.0001542124,0.0000258731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009650738,"about_ca_system_score_gemma":0.000114277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003107051,"about_ca_topic_score_gemma":0.0002091756,"domain_scores_codex":[0.9982364,0.0001819606,0.0006981391,0.0001366522,0.000475793,0.0002711252],"domain_scores_gemma":[0.9985559,0.0002868884,0.0003462418,0.0002402338,0.0002557494,0.0003149915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006824256,0.0006672144,0.9717078,0.0001646043,0.0004534525,0.003482116,0.002330561,0.0001778268,0.0000900689,0.000002646233,0.01159838,0.002501145],"study_design_scores_gemma":[0.01968154,0.00336126,0.9637411,0.002057367,0.0007690004,0.005848026,0.001209774,0.0001760271,0.0002675574,0.00007394005,0.00264701,0.0001673558],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968475,0.0003702355,0.000004350472,0.00146345,0.000171513,0.0006485772,0.00002691175,0.000016588,0.0004508618],"genre_scores_gemma":[0.9985074,0.0005384492,0.00005840971,0.0004031772,0.00007621948,0.000007426265,0.00003265389,0.00002029817,0.000355952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01285729,"threshold_uncertainty_score":0.5081619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2899771516","doi":"10.25251/skin.2.6.5","title":"Efficacy of a Silicone-Based Gel Containing Pracaxi Oil (Pentaclethra macroloba) for Treating Post-Surgical Scars","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Scars; Silicone; Surgery; Silicone oil; Randomized controlled trial","authors":[{"name":"Mark S. Nestor","is_ca":false},{"name":"Brian Berman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02279922151868099,"gpt":0.3523882437653737,"spread":0.3295890222466927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001340369,0.0002284624,0.0008954275,0.0002105118,0.0001990433,0.00001029384,0.0002891948,0.0001300289,0.0002486286],"category_scores_gemma":[0.001387741,0.0001080084,0.0002524657,0.0002289667,0.0008975844,0.0000428443,0.00003998784,0.000398391,0.000006574149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001013415,"about_ca_system_score_gemma":0.0003421855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007885387,"about_ca_topic_score_gemma":0.00001096158,"domain_scores_codex":[0.997362,0.0002285587,0.0009538719,0.0001691818,0.0008558287,0.0004306245],"domain_scores_gemma":[0.9949532,0.002673543,0.000780205,0.0003206025,0.00101297,0.0002595018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"case_report","study_design_scores_codex":[0.188064,0.004845256,0.02656462,0.001519056,0.005229445,0.02441988,0.01405219,0.000196081,0.09670761,0.0005732552,0.01273317,0.6250954],"study_design_scores_gemma":[0.1543416,0.1383959,0.0121383,0.0107042,0.007081451,0.5172881,0.01469659,0.004879402,0.08653474,0.0005397243,0.05247739,0.0009225489],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979988,0.001670988,0.00009972823,0.01378812,0.0002716989,0.0003875644,0.00001082839,0.00001616215,0.003766924],"genre_scores_gemma":[0.9967645,0.0002452076,0.0007279586,0.0006593054,0.0009081685,0.000005021998,0.000009731518,0.0000303612,0.000649702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6241729,"threshold_uncertainty_score":0.4404455,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388627499","doi":"10.25251/skin.7.supp.241","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Clinical endpoint; Apremilast; Clinical trial; Internal medicine; Randomized controlled trial; Tolerability; Adverse effect; Gastroenterology; Dermatology; Psoriatic arthritis","authors":[{"name":"Howard Sofen","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"C. Paul","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Lynda Spelman","is_ca":false},{"name":"Seong Jun Seo","is_ca":false},{"name":"Thierry Passeron","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Victoria Berger","is_ca":false},{"name":"Eleni Vritzali","is_ca":false},{"name":"Kim Hoyt","is_ca":false},{"name":"Matthew J. Colombo","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Matthias Augustin","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Andrew Alexis","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03370635970462376,"gpt":0.3210922749445532,"spread":0.2873859152399295,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008589252,0.0001749602,0.0007661364,0.0004014934,0.00005512532,0.000004732276,0.0003628563,0.0001592838,0.0001559168],"category_scores_gemma":[0.002461471,0.00008612783,0.0001095354,0.0004965267,0.0003297474,0.00004441391,0.00003449755,0.0003708861,0.00001646522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003904472,"about_ca_system_score_gemma":0.00009433217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009505526,"about_ca_topic_score_gemma":0.0001165644,"domain_scores_codex":[0.9956334,0.002769113,0.0010308,0.0001286281,0.000140195,0.0002978974],"domain_scores_gemma":[0.9934704,0.005559613,0.0006262749,0.0002555152,0.0000622656,0.00002587729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1597775,0.001276953,0.005740736,0.0001251441,0.001906778,0.01107337,0.077103,0.0001214276,0.4949413,0.0009192175,0.07286288,0.1741517],"study_design_scores_gemma":[0.2222398,0.02786207,0.2757035,0.007194477,0.004780856,0.09992779,0.08342546,0.00008154492,0.06611753,0.0168151,0.1942351,0.001616825],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988863,0.006313765,0.000005830953,0.00371282,0.0006278027,0.0002905141,0.00003817626,0.00000728826,0.0001408326],"genre_scores_gemma":[0.9938886,0.005180003,0.00001636917,0.00026091,0.0001358691,0.000005909298,0.000008569813,0.00001379912,0.0004900212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4288238,"threshold_uncertainty_score":0.3512191,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4400930743","doi":"10.25251/skin.8.supp.406","title":"Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Computer science; Dermatology","authors":[{"name":"April W. Armstrong","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Howard Sofen","is_ca":false},{"name":"Akimchi Morita","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Mamitaro Ohtsuki","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Thierry Passeron","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Matthew J. Colombo","is_ca":false},{"name":"John Vaile","is_ca":false},{"name":"Eleni Vritzali","is_ca":false},{"name":"Kim Hoyt","is_ca":false},{"name":"Carolin Daamen","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02818014222467983,"gpt":0.3017047100186793,"spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004107199,0.0002734667,0.0008538619,0.0001603629,0.0001905037,0.0000278045,0.0002891888,0.0002150057,0.0002170849],"category_scores_gemma":[0.001952354,0.0001235148,0.0001226403,0.0002157417,0.0004194897,0.00006928897,0.00005634006,0.0005816698,0.00002685806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004276483,"about_ca_system_score_gemma":0.00009701909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002004022,"about_ca_topic_score_gemma":0.0001222922,"domain_scores_codex":[0.9965476,0.001548362,0.001245997,0.0002419543,0.0001275815,0.0002885339],"domain_scores_gemma":[0.9891089,0.01003813,0.0004409634,0.0002881415,0.00006518677,0.00005865321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.09416894,0.0006348892,0.0003884353,0.00007587906,0.005905161,0.003726935,0.04623614,0.00003535724,0.07761314,0.001143866,0.04859599,0.7214753],"study_design_scores_gemma":[0.1611595,0.01030901,0.008601205,0.006697407,0.01112386,0.05758612,0.01628518,0.0000826999,0.02579541,0.008297715,0.6928757,0.001186189],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8924461,0.08914056,0.00005472797,0.01473886,0.002113142,0.0004323636,0.0003472713,0.0000255115,0.0007014679],"genre_scores_gemma":[0.9712721,0.02683293,0.00004640475,0.0002812829,0.0008449149,0.000002357304,0.00005738642,0.00002353338,0.0006391099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7202891,"threshold_uncertainty_score":0.5036787,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213872593","doi":"10.25251/skin.5.supp.59","title":"Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Interim; Term (time); Interim analysis; Medicine; Dermatology; Pediatrics; Psychology; Internal medicine; Political science; Clinical trial; Physics","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"J.‐P. Lacour","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Vivian Laquer","is_ca":false},{"name":"Stefan Beissert","is_ca":false},{"name":"Andreas Wollenberg","is_ca":false},{"name":"Pedro Herranz","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"Ketty Peris","is_ca":false},{"name":"Stine Fangel","is_ca":false},{"name":"Hidehisa Saeki","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01493705308753436,"gpt":0.2688596138407451,"spread":0.2539225607532108,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002242773,0.0002645693,0.0009431099,0.0003938175,0.00008582271,0.00001968364,0.0002652066,0.00008700608,0.0005450315],"category_scores_gemma":[0.0002198918,0.0001502489,0.0001399354,0.0008362775,0.0001460237,0.0001582293,0.00004334198,0.0003801433,0.000006171073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001196102,"about_ca_system_score_gemma":0.0002018354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006510229,"about_ca_topic_score_gemma":0.000959274,"domain_scores_codex":[0.9976525,0.0003311446,0.0008535943,0.0002197967,0.0006055938,0.0003373896],"domain_scores_gemma":[0.9980261,0.0001884534,0.0003757519,0.0004554286,0.0005890556,0.0003651648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002223381,0.0008740706,0.9772298,0.0001276994,0.001773654,0.01244634,0.001447322,0.0004092955,0.000239955,0.000002707553,0.0007103127,0.002515409],"study_design_scores_gemma":[0.006303816,0.001311414,0.9783087,0.0009142324,0.003046334,0.008109422,0.0005280891,0.000236305,0.0009587304,0.00007494613,0.00003395987,0.0001740537],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967666,0.0006541827,0.0002066711,0.001651322,0.0001575731,0.0003098533,0.0000130566,0.00001453474,0.0002262032],"genre_scores_gemma":[0.9964057,0.0001894106,0.0001287229,0.00277802,0.0001002912,0.000004526587,0.0001060712,0.00002571108,0.0002616148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004336915,"threshold_uncertainty_score":0.6126972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388627694","doi":"10.25251/skin.7.supp.271","title":"Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","authors":[{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Stephan Weidinger","is_ca":false},{"name":"Eric L. Simpson","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Alan D. Irvine","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Hany Elmaraghy","is_ca":false},{"name":"Louise DeLuca-Carter","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Chaoran Hu","is_ca":false},{"name":"Fan Emily Yang","is_ca":false},{"name":"Evangeline Pierce","is_ca":false},{"name":"Laia Bardolet","is_ca":false},{"name":"Diamant Thaçi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006471958431611242,"gpt":0.2525797674709807,"spread":0.2461078090393695,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002758824,0.0001367951,0.0005399379,0.0003256525,0.00004502567,0.000003735959,0.0001451992,0.00004128617,0.0001170254],"category_scores_gemma":[0.0003448798,0.00008037786,0.00003512765,0.0004623197,0.0001421096,0.00003816479,0.00004858223,0.0002176484,0.00001526606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004667677,"about_ca_system_score_gemma":0.00009440503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003003863,"about_ca_topic_score_gemma":0.0000227912,"domain_scores_codex":[0.9985706,0.000103727,0.0005317763,0.0001093795,0.0004590908,0.0002254409],"domain_scores_gemma":[0.9988518,0.0003353087,0.0001826871,0.0002138659,0.0001820518,0.000234237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05843944,0.0009763599,0.6932897,0.0006105802,0.001273962,0.01558023,0.03417121,0.005026904,0.0002330974,0.0002059071,0.1410712,0.04912147],"study_design_scores_gemma":[0.01381577,0.001775488,0.9732143,0.001577896,0.0002813641,0.006432807,0.0006899354,0.0001215287,0.0001381213,0.0004087408,0.001415205,0.0001288841],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900612,0.0002172198,0.0000578789,0.008778093,0.0001042131,0.0004177742,0.000009040178,0.00001069091,0.0003438799],"genre_scores_gemma":[0.9966827,0.0001262094,0.0001198351,0.00279657,0.00007139677,0.000001619752,0.000005753538,0.00001773716,0.000178201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2799246,"threshold_uncertainty_score":0.3277714,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409574408","doi":"10.25251/skin.10.supp.573","title":"Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bausch Health; LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Term (time); Medicine; Pediatrics; Dermatology; Physics","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"Vivian Laquer","is_ca":false},{"name":"Richard G. Langley","is_ca":false},{"name":"Chih-ho Hong","is_ca":false},{"name":"Christian Bjerregård Øland","is_ca":false},{"name":"Le Gjerum","is_ca":false},{"name":"Ann‐Marie Tindberg","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005786183515752849,"gpt":0.2590034322650996,"spread":0.2532172487493468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593194,0.0001355747,0.0005594997,0.0002452884,0.00004150491,0.000004083636,0.00009953609,0.00005653765,0.00001494481],"category_scores_gemma":[0.000241635,0.00007987606,0.00003478156,0.0002062181,0.0001479458,0.00003136212,0.00002207604,0.0001606555,4.776943e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003439,"about_ca_system_score_gemma":0.00008487758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002235418,"about_ca_topic_score_gemma":0.0000917365,"domain_scores_codex":[0.9989799,0.00007077467,0.0004778603,0.0001148482,0.0001862424,0.0001704159],"domain_scores_gemma":[0.999163,0.0002344508,0.0001443031,0.0001472398,0.0001431959,0.0001678611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09081668,0.0005228919,0.8296143,0.002798235,0.0006255709,0.004397547,0.01148631,0.0003134701,0.0002848886,0.00005460394,0.007026065,0.05205941],"study_design_scores_gemma":[0.01605048,0.001217287,0.9573717,0.01146439,0.0004708341,0.01228151,0.0003884913,0.00009330097,0.0003646281,0.00007095977,0.0001332037,0.00009317602],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939926,0.001467104,0.00034056,0.003357048,0.000092255,0.0006325623,0.00000770259,0.000005312326,0.0001048086],"genre_scores_gemma":[0.998062,0.0004715775,0.00006609016,0.001130228,0.00004361273,0.000002677631,0.000003245413,0.00001082746,0.0002098093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1277574,"threshold_uncertainty_score":0.3257251,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3004321152","doi":"10.25251/skin.4.supp.60","title":"Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Pharmacokinetics; Medicine; Dermatology; Pharmacology","authors":[{"name":"Lawrence F. Eichenfield","is_ca":false},{"name":"Boni E. Elewski","is_ca":false},{"name":"Ted Rosén","is_ca":false},{"name":"Aditya Gupta","is_ca":true},{"name":"Wendy Cantrell","is_ca":false},{"name":"Radhakrishnan Pillai","is_ca":false},{"name":"Abby Jacobson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01845050729206081,"gpt":0.2905141314512494,"spread":0.2720636241591886,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118435,0.0001207997,0.0004315975,0.0000689201,0.00003564182,0.00000146619,0.00008981603,0.00003403405,0.00008229143],"category_scores_gemma":[0.0002534918,0.00005516256,0.0001165472,0.0001443715,0.0001102733,0.00001629397,0.00001422038,0.00007838391,7.225952e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005907159,"about_ca_system_score_gemma":0.00005606223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002894784,"about_ca_topic_score_gemma":0.000003732998,"domain_scores_codex":[0.9988489,0.00005372979,0.0005759519,0.00008204563,0.0003110047,0.0001283537],"domain_scores_gemma":[0.9984381,0.0007813548,0.0003667059,0.0001104729,0.0001764436,0.0001269195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05873181,0.008792471,0.4249324,0.0009523405,0.001939895,0.0003221848,0.009957265,0.0003398744,0.002192707,0.00007172626,0.008283365,0.483484],"study_design_scores_gemma":[0.08741963,0.06000806,0.8149405,0.0005597982,0.01321861,0.0005652111,0.0006130568,0.002603716,0.002958725,0.0002227752,0.01665707,0.0002328976],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823269,0.008777083,0.0001188853,0.007862733,0.0001523571,0.0006438502,0.00002180595,0.000002473025,0.00009386124],"genre_scores_gemma":[0.9865857,0.01265443,0.0000794644,0.0001762731,0.0004369347,0.000002641966,0.000006588078,0.00001009341,0.00004791966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4832511,"threshold_uncertainty_score":0.2249464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3105819045","doi":"10.25251/skin.4.supp.113","title":"A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Horticultural and Viticultural Research","field":"Agricultural and Biological Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Lotion; Tazarotene; Spreadability; Dermatology; Medicine; Chemistry; Pharmacology; Food science","authors":[{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Emil Tanghetti","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1191770214751348,"gpt":0.3547450848673582,"spread":0.2355680633922234,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158359,0.0001340024,0.0005510816,0.000007719666,0.0001303691,0.000007555145,0.000525828,0.00008950027,0.0002289977],"category_scores_gemma":[0.001599146,0.00002939693,0.000237814,0.0004577703,0.0007106081,0.00008201288,0.00006749757,0.000440625,0.000002931324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002620693,"about_ca_system_score_gemma":0.00004095867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001935273,"about_ca_topic_score_gemma":0.0002429936,"domain_scores_codex":[0.9971425,0.0007204167,0.001035324,0.0001234158,0.0008012137,0.0001771484],"domain_scores_gemma":[0.9966077,0.001707183,0.000818748,0.00007797992,0.0006197229,0.0001686565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.005980251,0.0004326688,0.003283788,0.00004798193,0.0002271304,0.00001830522,0.002390585,0.0002350014,0.9304852,0.0001255825,0.002829748,0.05394371],"study_design_scores_gemma":[0.005365969,0.05506673,0.4645641,0.001024995,0.001208095,0.001479042,0.02594136,0.001833659,0.4339401,0.001289407,0.00772263,0.0005639401],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696661,0.0002949223,0.00001209119,0.02908224,0.0002202022,0.0003102023,0.00001149252,0.000004981786,0.0003978167],"genre_scores_gemma":[0.9988101,0.0002823684,0.00002970794,0.0001544724,0.000672981,9.135096e-7,0.00000417156,7.349695e-7,0.00004456558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4965452,"threshold_uncertainty_score":0.2618265,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4241580772","doi":"10.25251/skin.4.supp.30","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Psoriasis; Baseline (sea); Phase (matter); Randomized controlled trial; Internal medicine; Biology; Physics","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Anna M Tailman","is_ca":false},{"name":"Leon Kircik","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01703836544243391,"gpt":0.2787548648414456,"spread":0.2617164993990116,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009728269,0.0002237563,0.00099724,0.00006574206,0.000119888,0.000004964129,0.00014889,0.00006807105,0.00008641665],"category_scores_gemma":[0.0009227574,0.00009993205,0.00009281119,0.0001181801,0.0003282816,0.0000235625,0.00001912843,0.0001235677,0.000001411258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002724913,"about_ca_system_score_gemma":0.0000612525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004295038,"about_ca_topic_score_gemma":0.00001214775,"domain_scores_codex":[0.9980723,0.0007555825,0.0007755524,0.0001460974,0.00007819173,0.0001722489],"domain_scores_gemma":[0.9949757,0.004163937,0.0005063724,0.0001669786,0.0001100917,0.0000768775],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8233168,0.004404357,0.0007694944,0.00006377052,0.002887898,0.0002507575,0.02028054,0.00001233018,0.008662681,0.0000196131,0.002326326,0.1370054],"study_design_scores_gemma":[0.887647,0.04667471,0.002888742,0.0004052815,0.0136959,0.001563169,0.007610732,0.0004120868,0.003575601,0.0001107841,0.03504036,0.0003756022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560624,0.03656057,0.0002133457,0.00504457,0.0003924133,0.001549524,0.0001645232,0.000005801733,0.000006835387],"genre_scores_gemma":[0.9748024,0.02458313,0.00001920644,0.0001595197,0.0002320214,0.0000175995,0.00005052328,0.00001530397,0.000120263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1366298,"threshold_uncertainty_score":0.4075111,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2987175910","doi":"10.25251/skin.3.supp.37","title":"Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Oncology; Adalimumab; Disease","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"A.B. Gottlieb","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"C. Leonardi","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Marion Boehnlein","is_ca":false},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Catherine Arendt","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0386763758361398,"gpt":0.3220570760310816,"spread":0.2833807001949418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005621527,0.0003859189,0.002007395,0.0002063524,0.0001224184,0.000009108314,0.0003115982,0.0002015093,0.001095988],"category_scores_gemma":[0.0005640694,0.0001887585,0.0004337946,0.00010352,0.000218281,0.00006033141,0.00002723734,0.000128923,0.00004040095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008826118,"about_ca_system_score_gemma":0.0001231985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002516262,"about_ca_topic_score_gemma":0.00006438011,"domain_scores_codex":[0.997393,0.000608121,0.001281542,0.0002242992,0.0001450363,0.0003479767],"domain_scores_gemma":[0.9926362,0.005398683,0.001282643,0.0004261844,0.0001789474,0.00007735362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1252684,0.003565667,0.01217975,0.0001130426,0.02394477,0.0007001122,0.01390657,0.00005664625,0.338724,0.0004278621,0.005164487,0.4759486],"study_design_scores_gemma":[0.5755968,0.07733867,0.010468,0.001372692,0.03684415,0.02884766,0.007322596,0.00007369266,0.2149974,0.005583938,0.04021316,0.001341196],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795854,0.0139464,0.0001356387,0.00270537,0.002098683,0.001126203,0.0002404744,0.00001634431,0.0001454507],"genre_scores_gemma":[0.9963656,0.002167189,0.0001470384,0.00004758327,0.000543348,0.00001121907,0.00006230647,0.00003400342,0.0006217178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4746074,"threshold_uncertainty_score":0.9998171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309317883","doi":"10.25251/skin.6.supp.57","title":"Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Intertriginous; Dermis; Tolerability; Psoriasis; Dermatology; Roflumilast; Medicine; Plaque psoriasis; Discontinuation; Sex organ; Surgery; Internal medicine; Pathology; Adverse effect; Biology; COPD","authors":[{"name":"Laura K. Ferris","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Jennifer Soung","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"David Krupa","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02331314075009889,"gpt":0.284818307337959,"spread":0.2615051665878601,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002512709,0.0003437912,0.00140959,0.0002481185,0.0002072838,0.00001434882,0.0003535443,0.00006498067,0.0004487465],"category_scores_gemma":[0.004383297,0.0001559084,0.0001070577,0.000311763,0.0005332282,0.00005441065,0.0001554011,0.0007405888,6.719532e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003391015,"about_ca_system_score_gemma":0.0005806856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003885933,"about_ca_topic_score_gemma":0.0001238528,"domain_scores_codex":[0.9952845,0.001000237,0.001879554,0.0003050758,0.001222743,0.0003078649],"domain_scores_gemma":[0.9923852,0.005008506,0.001551421,0.000607576,0.000238794,0.0002085074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8034833,0.02489758,0.03197956,0.0005137176,0.005044993,0.004165354,0.03897624,0.001554216,0.00474383,0.00003685263,0.01195255,0.0726518],"study_design_scores_gemma":[0.4076375,0.210914,0.2966078,0.009834422,0.0109106,0.008529305,0.03521722,0.001004132,0.00757862,0.0007171789,0.009719542,0.001329664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904333,0.002749572,0.00001713702,0.004570879,0.0002090395,0.001687664,0.0002366106,0.00001203118,0.00008375155],"genre_scores_gemma":[0.9984936,0.0005041402,0.0000198316,0.0005491583,0.0002491683,0.00001685521,0.000059371,0.00003594438,0.00007199278],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3958458,"threshold_uncertainty_score":0.6357759,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3104939465","doi":"10.25251/skin.4.supp.102","title":"Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Concomitant; Atopic dermatitis; Medicine; Dermatology; Randomized controlled trial; Internal medicine","authors":[{"name":"Stephan Weidinger","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Thomas Bieber","is_ca":false},{"name":"Andrew Alexis","is_ca":false},{"name":"Boni E. Elewski","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"DirkJan Hignen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01553185210748632,"gpt":0.2618408314692068,"spread":0.2463089793617205,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002302149,0.0002174065,0.0008822759,0.00006011217,0.00008066787,0.000009557561,0.0002613523,0.00009078434,0.00006869316],"category_scores_gemma":[0.001906317,0.0001024632,0.00007124175,0.0001862201,0.0003594097,0.00006333696,0.00004152525,0.000537801,0.000002502557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005361547,"about_ca_system_score_gemma":0.000204448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005200917,"about_ca_topic_score_gemma":0.00004692279,"domain_scores_codex":[0.9974186,0.0003380543,0.001239432,0.0001789516,0.0005940226,0.000230891],"domain_scores_gemma":[0.9970328,0.001606316,0.0004988873,0.0002747657,0.000263719,0.0003235512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9335065,0.001485883,0.01349876,0.0001379295,0.0007252099,0.004281431,0.02255139,0.0004125375,0.0001382114,0.00004508285,0.0124853,0.01073171],"study_design_scores_gemma":[0.8010223,0.02212889,0.15566,0.003525668,0.002143441,0.007405617,0.003219445,0.001745143,0.0005089834,0.0003009153,0.001946374,0.0003932722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9720619,0.0005911873,0.0001369876,0.02579012,0.0002091708,0.0009169555,0.00007451928,0.000008541682,0.0002106711],"genre_scores_gemma":[0.9937819,0.0002292994,0.00007533294,0.005487414,0.0003662731,0.000002824421,0.00002523771,0.00001626549,0.00001545865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1421612,"threshold_uncertainty_score":0.4178329,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2986312172","doi":"10.25251/skin.3.supp.39","title":"Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Certolizumab pegol; Placebo; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Dermatology; Adalimumab; Pathology; Alternative medicine","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"Bruce Strober","is_ca":true},{"name":"Richard G. Langley","is_ca":true},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Catherine Arendt","is_ca":false},{"name":"Marion Boehnlein","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02894658660659985,"gpt":0.2972223779139177,"spread":0.2682757913073179,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001808312,0.0004714509,0.003121156,0.0003434007,0.0001191255,0.00001029613,0.0008491786,0.0002460972,0.0006445017],"category_scores_gemma":[0.002076497,0.0002435952,0.0002437741,0.000180764,0.000620013,0.0001843049,0.0002115417,0.0005283683,0.00003193659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001041937,"about_ca_system_score_gemma":0.000157261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004686284,"about_ca_topic_score_gemma":0.0006016374,"domain_scores_codex":[0.9954609,0.001632383,0.001881662,0.0003335224,0.0002335488,0.0004580009],"domain_scores_gemma":[0.9894268,0.007847318,0.001584892,0.0008221078,0.0002379393,0.00008092752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9392323,0.000895613,0.001005668,0.00006927414,0.01024581,0.000698123,0.00732538,0.00003208776,0.01998694,0.00002647993,0.002262041,0.01822028],"study_design_scores_gemma":[0.9674029,0.002890077,0.000359471,0.001237989,0.006990627,0.007827056,0.008017326,0.0004169089,0.0030957,0.0006407458,0.0008034573,0.0003176959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9210989,0.07171986,0.000115763,0.002983721,0.001982027,0.001664938,0.0002068642,0.00001482035,0.0002131393],"genre_scores_gemma":[0.9838032,0.01531866,0.00007346451,0.0001152302,0.0002628663,0.0000118332,0.00008919304,0.00003233581,0.0002931826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06270436,"threshold_uncertainty_score":0.9933523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3085571220","doi":"10.25251/skin.4.supp.42","title":"Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"XBiotech; Kyowa Kirin Pharmaceutical Development; National Institutes of Health; Incyte; Dermira; Valeant Pharmaceuticals International; Celgene; Allergan; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Post-hoc analysis; Psoriasis; Post hoc; Medicine; Internal medicine; Dermatology","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Nehal N. Mehta","is_ca":false},{"name":"Alice B. Gottlieb","is_ca":false},{"name":"Alan M. Mendelsohn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0407345546950072,"gpt":0.3128386053145739,"spread":0.2721040506195667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091502,0.0002576199,0.001243922,0.0001487299,0.0001344157,0.000008091738,0.0008022271,0.0001167122,0.0001948582],"category_scores_gemma":[0.001372933,0.0001265656,0.0001114458,0.0007697897,0.0005118694,0.00008810936,0.0002027628,0.0003936715,0.00001190625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002786066,"about_ca_system_score_gemma":0.00008056683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004451876,"about_ca_topic_score_gemma":0.0001916618,"domain_scores_codex":[0.9973196,0.001019659,0.0008938123,0.0002702013,0.0001950437,0.0003017107],"domain_scores_gemma":[0.9954718,0.002896741,0.000744106,0.0006411221,0.0001787713,0.00006743776],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08276822,0.002425799,0.01261509,0.0001493218,0.1461674,0.002755989,0.1429738,0.001187716,0.4030764,0.0000992311,0.1193925,0.08638843],"study_design_scores_gemma":[0.1580485,0.03661861,0.1100094,0.002885924,0.2187067,0.01124917,0.1936325,0.0005743319,0.04503962,0.0005454126,0.2201312,0.002558602],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7634856,0.2303353,0.000008093038,0.004953783,0.0002841771,0.0001623249,0.0007452808,0.000006934009,0.00001850217],"genre_scores_gemma":[0.959379,0.03986433,0.00005640911,0.0003238817,0.00007769468,8.648072e-7,0.0002042423,0.00001636401,0.00007719647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3580368,"threshold_uncertainty_score":0.5161194,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765131124","doi":"10.25251/skin.2.supp.54","title":"Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; European Academy of Allergy and Clinical Immunology","keywords":"Medicine; Chronic urticaria; Omalizumab; Dermatology; Primary care; Immunology; Immunoglobulin E; Antibody; Family medicine","authors":[{"name":"Gordon Sussman","is_ca":false},{"name":"Jacques Hébert","is_ca":false},{"name":"Wayne Gulliver","is_ca":false},{"name":"Charles Lynde","is_ca":false},{"name":"William H. Yang","is_ca":false},{"name":"Olivier Chambenoit","is_ca":false},{"name":"António Vieira","is_ca":false},{"name":"Frederica DeTakaosy","is_ca":false},{"name":"Lenka Řihakova","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005904810974161413,"gpt":0.2346256141413623,"spread":0.2287208031672009,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001021545,0.0003393616,0.001273051,0.0002453299,0.0001722546,0.00000524808,0.0005443678,0.0001779616,0.000072998],"category_scores_gemma":[0.0008590728,0.0001503361,0.0003107101,0.0006792409,0.001156098,0.00006628292,0.0001112986,0.0006885854,0.000001996097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003728656,"about_ca_system_score_gemma":0.0007374072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001077752,"about_ca_topic_score_gemma":0.0000487276,"domain_scores_codex":[0.9950935,0.0004706659,0.002011495,0.0002418496,0.001804285,0.0003782188],"domain_scores_gemma":[0.9951639,0.0005692152,0.001810467,0.001057965,0.001200493,0.0001979836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1878002,0.02876003,0.260639,0.001127782,0.1354102,0.02666925,0.1503263,0.0014433,0.1888491,0.000848964,0.003664108,0.01446181],"study_design_scores_gemma":[0.09911314,0.2656878,0.3371435,0.0218755,0.174307,0.06001182,0.01122098,0.0009507831,0.02740437,0.0009658171,0.0003103681,0.001008955],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993935,0.001397229,0.00005574955,0.001161514,0.0007266892,0.001164271,0.00002496721,0.00001315809,0.001521457],"genre_scores_gemma":[0.9990146,0.0001374512,0.0001324099,0.00007732818,0.0003966182,0.000003714465,0.00000814828,0.00004678777,0.0001829857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2369278,"threshold_uncertainty_score":0.613053,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4324057774","doi":"10.25251/skin.7.supp.111","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Cohort; Roflumilast; Internal medicine; Psoriasis; Randomized controlled trial; Open label; Surgery; Dermatology; COPD","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Kim Papp","is_ca":true},{"name":"Laura K. Ferris","is_ca":false},{"name":"David Adam","is_ca":true},{"name":"Hwanhee Hong","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David Krupa","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05145775588564373,"gpt":0.3755849522784312,"spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002576355,0.0002383401,0.001328888,0.0001424122,0.0001006836,0.00000648273,0.0003657409,0.00009706446,0.0003312099],"category_scores_gemma":[0.002481898,0.000123032,0.00006036066,0.0006184215,0.0006401175,0.0001209069,0.0001658704,0.0007206948,0.000002273718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001395887,"about_ca_system_score_gemma":0.000291076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009619907,"about_ca_topic_score_gemma":0.0004360074,"domain_scores_codex":[0.9968469,0.0004329906,0.001454426,0.0002162855,0.0007447278,0.0003046645],"domain_scores_gemma":[0.9929587,0.005103115,0.001078477,0.0003322314,0.0002900855,0.0002373639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9273454,0.004411357,0.0006507384,0.000435212,0.001037725,0.0008935079,0.004911143,0.00008208703,0.004323584,0.00002626714,0.001450573,0.05443244],"study_design_scores_gemma":[0.828167,0.1076731,0.01332383,0.009735316,0.003636124,0.004330417,0.005563332,0.001341487,0.004134323,0.0004710797,0.02122217,0.0004017713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806349,0.003905123,0.00003649696,0.0129112,0.0003386021,0.001224586,0.00006080843,0.000009066797,0.0008792478],"genre_scores_gemma":[0.9798016,0.01915753,0.0001014801,0.0001732904,0.0006770929,0.000004133795,0.00001136763,0.00002147151,0.00005201773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1032618,"threshold_uncertainty_score":0.5017101,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}